Cosmos Health reports Q1 EPS (3c) vs. (11c) last year

Reports q1 revenue $13.7M vs. $14.6M last year. Greg Siokas, CEO of Cosmos Health (COSM), stated: “We are pleased with our strong first-quarter performance and the steady progress across multiple strategic areas. Gross profit and gross margins increased significantly, supported by an improved product mix and stronger operating leverage. Our continued focus on efficiency and disciplined cost management is yielding tangible results, as reflected in our return to profitability on both an Adjusted EBITDA and Adjusted Net Income basis. Importantly, we are approaching a key milestone, having substantially reduced our operating cash burn and moving closer to operational cash flow breakeven. Moreover, we ended the quarter with higher stockholders’ equity and improved liquidity, including an increased cash balance. Our balance sheet remains prudent, underpinned by modest leverage and a diversified asset base. Operationally, we continue to advance strategic initiatives across the group. Our R&D pipeline is evolving, with multiple projects underway, including our CCX0722 weight management solution which has entered its final development phase and is progressing toward launch. We are also scaling our high-margin contract manufacturing segment through new long-term agreements, while expanding the global footprint of Sky Premium Life, our flagship nutraceutical brand. In parallel, we are growing our C-Scrub antiseptics line, including continued progress in the lucrative UK market. Finally, I want to reaffirm my personal commitment to Cosmos. Since December 20, 2024, I have increased my personal shareholding by over 2.7 million shares, representing an investment of more than $1.3 million, which reflects my strong confidence in the Company’s strategy and long-term growth potential.”